Feature|Videos|October 21, 2025

Panel Introduction

The FDA has established a formal regulatory pathway for whole-room microbial reduction devices, transforming a fragmented space into one with more straightforward rules and expectations. With hospitals still struggling to thoroughly disinfect high-touch surfaces—and many turning to UV and other adjunct tools—clarity on compliance and claims is overdue. In this section, our panel of an EVS operations leader, a hospital epidemiologist, and a former FDA infection-control chief unpacks what the new oversight means for patient safety, procurement, and the future of advanced disinfection.

Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.